A powerful class of antibiotics provides life-saving relief for people with cystic fibrosis; however, a new study for the first time reveals the levels at which high cumulative dosages over time significantly increases the risk of permanent hearing loss in these patients.
Cystic fibrosis, or CF, is an inherited chronic disease that affects the lungs and digestive system. Approximately 30,000 people in the United States and 70,000 worldwide are living with the disease.
The study, to be published Feb. 23 in the Journal of Cystic Fibrosis, suggests physicians who treat patients with cystic fibrosis may be able to consider alternative strategies for treating the symptoms of respiratory infections associated with CF, especially if patients are responsive to different classes of antibiotics. New medications are emerging that have shown a reduced toxic effect on both the kidneys and ears of these patients, while effectively treating infections.
"Preventing or ameliorating the effects of permanent [hearing loss] is crucial for patients with CF who already have a significantly compromised quality of life due to the disease," the authors concluded.
The study examined the medical records of 81 CF patients, aged 15 to 63 years, grouping them into four quartiles based on the cumulative dosage of aminoglycoside antibiotics administered intravenously. Researchers found that the two highest dosage groups were 4.79 times more likely to experience permanent hearing loss than the two quartiles with the lowest cumulative dosage exposure.
"This is an early step toward developing a model for predicting hearing loss in these patients," said lead author Angela Garinis, Ph.D., a senior research associate in the Oregon Hearing Research Center at OHSU and research audiologist with the VA Portland Health Care System.
Aminoglycosides inhibit bacterial protein synthesis, and they are often necessary to clear life-threatening respiratory infections. However, these medications can degrade auditory function in the inner ear as well as kidney function.
Previous research had demonstrated a greater risk of hearing loss from aminoglycoside antibiotics, but the new study is the first to factor in cumulative exposure over a patient's lifetime while also weighting the daily dosing schedule used by patients. The findings suggest it is imperative for physicians to routinely monitor hearing in any patient receiving aminoglycosides intravenously.
"This information will allow both the patient and the physician to discuss possible modifications to the treatment regimen, particularly if an alternative approach is or becomes available," according to the study.
Patients with cystic fibrosis are living longer, raising the importance of maintaining their quality of life over a longer period of time.
"People don't realize the trauma of hearing loss until after they've lost it," said senior author Peter Steyger, Ph.D., a professor of otolaryngology/head and neck surgery in the OHSU School of Medicine who lost hearing as a child after being treated with antibiotics for a case of meningitis at age 14 months. "Helen Keller said, 'Blindness separates people from things; deafness separates people from people.' It can lead to isolation, depression and cognitive decline."
In addition to Garinis and Steyger, authors include Campbell P. Cross, Priya Srikanth, Kelly Carroll, M. Patrick Feeney, Ph.D., Daniel B. Putterman, Au.D., David M. Cohen, M.D., and Jeffrey A. Gold, M.D., of OHSU; Douglas H. Keefe, Ph.D., of Boys Town National Research Hospital in Omaha, Nebraska; and Lisa L. Hunter, Ph.D., of Cincinnati Children's Hospital. Garinis, Feeney and Putterman have joint appointments at the National Center for Rehabilitative Auditory Research at the VA Portland Health Care System in Portland.
The research was supported by the National Institutes of Health CTSA grant (UL1TR000128) to the Oregon Clinical and Translational Research Institute and NIH-NIDCD Grant Awards: R01 DC004555, R01 DC012588, and R01 DC10202.
Story Source: Materials provided by Scienmag